Why the study?
Does invasive management improve survival in patients aged ≥85 years presenting with NSTEMI?
Does invasive management improve survival in patients aged ≥85 years presenting with NSTEMI?
In very elderly patients (≥85 years) with NSTEMI, invasive management is associated with improved survival without an increase in bleeding or stroke compared to conservative management.
May support invasive strategy in selected very elderly NSTEMI patients; leaves open need for RCTs to confirm.
In patients aged ≥85 years who presented with NSTEMI, invasive management was associated with improved survival without significant differences in bleeding or stroke. A randomised controlled study assessing the efficacy and safety of invasive management in very elderly patients with NSTEMI is warranted.
No takes yet. Share an insight, caveat, or question.
Kunniardy et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: